Is tesamorelin FDA-approved?

Yes — tesamorelin (Egrifta) was approved by the FDA in 2010 for HIV-associated lipodystrophy.

Tesamorelin Calculator

Also known as: Egrifta

GHS

Default: 5mg / 2mL / 1mgAdjust inputs to match your vial

About

What is Tesamorelin?

Tesamorelin (Egrifta) is an FDA-approved GHRH analogue indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy. The approved dose is 2 mg subcutaneously once daily. It is also studied off-label for visceral adiposity and cognitive endpoints.

Common vial sizes

1 mg	lyophilized powder
2 mg	lyophilized powder
5 mg	lyophilized powder
10 mg	lyophilized powder

Reference dose ranges

1 mg	≈ 40 U-100 units (at 5mg / 2mL)
1.4 mg	≈ 56 U-100 units (at 5mg / 2mL)
2 mg	≈ 80 U-100 units (at 5mg / 2mL)

Reconstitution

How it's typically prepared

Reconstitute with sterile water for injection per label, or with bacteriostatic water for compounded vials. Refrigerate.

FAQ

Frequently asked questions

Is tesamorelin FDA-approved?: Yes — tesamorelin (Egrifta) was approved by the FDA in 2010 for HIV-associated lipodystrophy.

Sources

References

Other GHS peptides

Notice

PeptideDose is an educational reference. It is not medical advice and does not replace consultation with a licensed healthcare provider. Doses shown in presets are derived from published protocols and product labels — they are not personal recommendations.